title: The pancreatic islets in spontaneously hypertensive rats: islet blood flow and insulin production.
abstract: The aim of the study was to investigate if hypertension affects pancreatic islet blood flow and endocrine function. For this purpose, spontaneously hypertensive rats (SHR) were compared with normotensive control Wistar-Kyoto rats (WKY). Both islet size and islet cell replication in 4-month-old SHR was increased compared with WKY. The (pro)insulin biosynthesis was reduced in islets isolated from SHR, whereas the insulin content was unchanged. A hyperinsulinemic response to glucose in vivo was observed in 4- and 12-month-old SHR. Pancreatic blood flow, measured using a microsphere technique, was lower in SHR than in WKY in rats aged 5 weeks, 4 months or 1 year. Islet blood flow was lower in 4-month-old and 1-year-old SHR. In 4-month-old animals, islet blood flow was unaffected by administration of enalaprilate and prazosin in both strains, but was markedly decreased by the administration of N(G)-methyl-L-arginine. It was concluded that the islets of SHR have a decreased insulin production in vitro and a decreased islet blood perfusion. The reasons for this are likely to be multifactorial. Because SHR maintained an essentially normal glucose tolerance, an adaptation of the beta-cells to the metabolic and hemodynamic changes imposed by hypertension occurred.
authors.affiliation: Department of Medical Cell Biology, Uppsala University, SE-751 23 Uppsala, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Iwase
authors.forename: S
authors.initials: S
authors.lastname: Sandler
authors.forename: P O
authors.initials: PO
authors.lastname: Carlsson
authors.forename: C
authors.initials: C
authors.lastname: Hellerström
authors.forename: L
authors.initials: L
authors.lastname: Jansson
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000375:Aging / Q000502:physiology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001786:Blood Glucose / Q000032:analysis; D004247:DNA / Q000378:metabolism; D015773:Enalaprilat / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006973:Hypertension / Q000473:pathology / Q000503:physiopathology*; D066298:In Vitro Techniques; D007328:Insulin / Q000096:biosynthesis* / Q000097:blood; D007515:Islets of Langerhans / Q000098:blood supply* / Q000378:metabolism* / Q000473:pathology; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D011918:Rats, Inbred SHR / Q000502:physiology*; D011921:Rats, Inbred WKY; D019323:omega-N-Methylarginine / Q000494:pharmacology
chemical_list: D000317:Adrenergic alpha-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001786:Blood Glucose; D004791:Enzyme Inhibitors; D007328:Insulin; D019323:omega-N-Methylarginine; D004247:DNA; D015773:Enalaprilat; D011224:Prazosin